ReviewBiomolecules2022
Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment.
Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Comparison of efficacy and safety of thrombus prevention strategies after abdominal and pelvic cancer surgery: Bayesian network based meta-analysis.Frontiers in oncology · 2025Pooled it
- Pooled it
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Clinical Characteristics and Prognosis of Thromboembolism in Elderly Patients With Stage IV Lung Cancer.Geriatrics & gerontology international · 2026Article
- [Lung Cancer with Pulmonary Embolism: Evidence-based Progress in Anticoagulation Assessment and Management].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Cancer-Associated Venous Thromboembolic Disease: Anatomoclinical Aspects and Risk Factors.Cureus · 2025Article
- Cancer-associated venous thromboembolism: a comprehensive review.Thrombosis journal · 2025Review
- Cancer-induced systemic pre-conditioning of distant organs: building a niche for metastatic cells.Nature reviews. Cancer · 2024Review
- Crosslink between atrial fibrillation and cancer: a therapeutic conundrum.Cardio-oncology (London, England) · 2024Review
- Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis.The oncologist · 2024Article
- Review
- The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.Cancers · 2023Review
- How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- Review
- Comparison of long-term complications in cancer patients with incidental and acute symptomatic venous thromboembolism.Frontiers in cardiovascular medicine · 2023Article
- Ten-Year Multicenter Retrospective Study Utilizing Machine Learning Algorithms to Identify Patients at High Risk of Venous Thromboembolism After Radical Gastrectomy.International journal of general medicine · 2023Article
- Real-World Evaluation of the Safety and Effectiveness of Apixaban & Rivaroxaban Lead-in Dosing Compared to Parenteral Lead-in Dosing in the Treatment of Venous Thromboembolism: A Multi-Center Retrospective Cohort Study.International journal of general medicine · 2023Article
- Topical Tranexamic Acid Can Be Used Safely Even in High Risk Patients: Deep Vein Thrombosis Examination Using Routine Ultrasonography of 510 Patients.Medicina (Kaunas, Lithuania) · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute thrombotic events can unveil occult cancer, as they are its first manifestation in about 20 to 30% of all cases. Malignancy interacts in an intricate way with the hemostatic system, promoting both thrombosis and bleeding. The main pathway involved in these reactions involves the activation of tumor-associated procoagulant factors, which eventually results in clot formation. The clinical manifestation of cancer-related thrombotic events mainly involves the venous side, and manifests in a broad spectrum of conditions, including unusual sites of venous thrombosis. The selection of patients who have a balanced risk-benefit profile for management of anticoagulation is complex, given individual patient goals and preferences, different prognosis of specific cancers, common comorbidities, potential drug-drug interactions, underweight states, and the competing risks of morbidity and mortality. Anticoagulant treatment in cancer settings is broadly debated, considering the potential application of direct oral anticoagulants in both thromboprophylaxis and secondary prevention, having demonstrated its efficacy and safety compared to conventional treatment. This review aims to provide a brief overview of the pathophysiology and management of cancer-related thrombosis, summarizing the results obtained in recent clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.